This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Attention-Deficit Hyperactivity Disorder
and you are
between 18 and 64
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.

Provided treatments

  • Drug: JNS001
  • Drug: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01323192. The sponsor of the trial is Janssen Pharmaceutical K.K. and it is looking for 284 volunteers for the current phase.
Official trial title:
A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day